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[5?] ABSTRACT 
The novel compound, 3-hydroxy-N-methylpyrroli 
done, is effective as a transdermal enhancer for the 
absorption of drugs through the skin of humans and 
animals. The 3-hydroxy-N-methylpyrrolidone is pre 
pared from delta-butyrolactone which is converted to‘ 
methyl 2,4-dibromobutyrate, this intermediate is re 
acted with methylamine to form N-methyl-2,4 
dibromobutyramide, this intermediate is converted to 
3~bromo-N-methyl-2-pyrrolidone by ring closure, and 
the 3-bromo-N-methyl-2-pyrrolidone is reacted with an 
alkaline earth metal carbonate or alkaline metal carbon 
ate to form 3-hydroxy-N-methyl-Z-pyrrolidone. 
3 Claims, 3 Drawing Sheets 
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3-HYDROXY-N-METHYLPYRROLIDONE AND 
USE AS TRANSDERMAL ENHANCER 
This is a division of application Ser. No. 07/263,384 
?led Oct. 27, 1988, now US. Pat. No. 4,973,708, dated 
Nov. 27, 1990. 
TECHNICAL FIELD 
This invention relates to a new composition for drug 
delivery and more particularly relates to use of the 
compound 3-hydroxy-N-methylpyrrolidone as a trans 
dermal enhancer for the absorption of drugs into hu 
mans and animals by absorption through the skin.. 
BACKGROUND ART 
Transdermal absorption is currently one of the fastest 
growing methods of drug delivery. Transdermal thera 
peutic systems are self-contained dosage forms that, 
when applied to intact skin, deliver drug(s) at a con 
trolled rate to the systemic circulation. Advantages of 
using the transdermal route include: enhanced thera 
peutic efficacy, reduction in the frequency of dosing, 
reduction of side effects due to optimization of the 
blood-concentration versus time pro?le, increased pa 
tient compliance due to elimination of multiple dosing 
schedules, bypassing the hepatic “?rst-pass" metabo 
lism, avoiding gastrointestinal incompatibilities and 
providing a predictable and extended duration of activ 
ity. However, the main function of the skin is to act as 
a barrier to entering compounds. As a consequence, 
transdermal therapy has so far been restricted to a lim 
ited number of drugs that possess the desirable physio 
chemical properties for diffusion across the skin barrier. 
One effective method of overcoming the barrier func 
tion of the skin is to include a penetration enhancer in 
the formulation of a transdermal therapeutic system. 
See Barry, Brian W.: Dermatological Formulations: Per 
cutaneous Absorption (Dekker, New York, 1983); 
Bronough et al, Percutaneous Absorption, Mechanisms 
Methodology-Drug Delivery, (Marcel Dekker, New 
York, N. Y. 1985); and Monkhouse et al, Transdermal 
drug delivery-problems and promises. Drug Dev. Ind. 
Pharm., 14, 183-209 (1988). 
A penetration enhancer is a chemical compound that, 
when included in a formulation, temporarily increases 
the permeability of the skin to the drug allowing more 
of the drug to be absorbed in a shorter period of time. 
Several different types of penetration enhancers have 
been reported such as dimethylsulfoxide, n-decyl 
methyl sulfoxide, N,N-dimethylacetamide, N,N-dime 
thylformamide, 1-dodecylazacycloheptan-Z-one 
(Azone), propylene glycol, ethanol, pyrrolidones such 
as N-methyl-Z-pyrrolidone (NMP) and surfactants. See 
Bronough et a1, supra, and Stoughton et a1, Azone: A 
New Non-toxic enhancer of percutaneous penetration. 
Drug Dev. Ind. Pharm., 9, 725-744 (1983). 
N-methyl-2-pyrrolidone is a versatile solvent which 
is miscible with water, ethyl alcohol, ether, chloroform, 
benzene, ethyl acetate and carbon disul?de. N-methyl 
pyrrolidone has been widely used as a solvent in indus 
trial processes such as petroleum re?ning, GAF Corp.: 
“M-Pyrol (N-methyl-Z-pyrrolidone) Handbook”, GAF 
Corp., New York, 1972. It is currently used as a solubi 
lizing agent in topical and parenteral veterinary phar 
maceuticals and is now under consideration for use in 
products intended for humans, Wells, D.A. et al: Dispo 
sition and Metabolism of Double-Labeled [3H and 14C] 
15 
20 
25 
35 
40 
50 
55 
65 
2 
N-methyl-Z-pyrrolidone in the Rat. Drug Met. Disps, 
16, 243-249 (1988). Animal and human experiments 
have shown very little irritation or sensitizaticn poten 
tial. Ames type assays and chronic exposure studies 
have not revealed any significant toxicity, Wells et a1, 
Mutagenicity and Cytotoxicity of N-methyl-2-pyrroli 
done and 4-(methyl amino) Butanoic Acid in the Sal 
monella/microsome Assay. J. Appl. T ox., 8, 135-139 
(1988). N-methylpyrrolidone has also been shown to be 
an effective penetration enhancer. Barry et a1, Optimi 
zation of Bioavailability of Topical Steroids: Penetra 
tion Enhancers Under Occlusion. J. Inv. Derm., 82, 
49-52 (1984); Akter et a1, Absorption Through Human 
Skin of Ibuprofen and Flurbiprofen; Effect of Dose 
Variation, Deposited Drug Films, Occlusion and the 
Penetration Enhancer N-methyl-Z-pyrrolidone. J. 
Pharm. Pharmacol., 37, 27-37 (1984); Holegaard et a1, 
Vehicle Effect on Topical Drug Delivery IV. Effect of 
N-methylpyrrolidone and Polar Lipids on Percutane 
ous Transport. Int. J. Pharm., 43, 233-240 (1988); 
Sugibayashi et al, Effect of Several Penetration En 
hancers on the Percutaneous Absorption of Indometha 
cin in Hairless Rat. Chem. Pharm. Bull, 36, 1519-1528 
(1988); Bennett et al, Optimization of Bioavailability of 
Topical Steroids: Non-Occluded penetration Enhancers 
Under Thermodynamic Control. J. Pharm. Pharmacol, 
37, 298-304 (1985); Sasaki et al, Enhancing Effect of 
Pyrrolidone Derivatives on Transdermal Drug Deliv 
ery. 1.1m. J. Pharm., 44, 15-24 (1988); Lee et al, Toxic 
ity of N-methyl-Z-pyrrolidone (NMP): Tetratog‘enic, 
Subchronic and Two-Year Inhalation Studies, Fund. 
Appl. T0x., 9, 222-235 (1987). ' 
There remains a need in the art of transdermal deliv 
ery for a penetration enhancer which is safe, effective, 
and provides advantages not known to penetration en 
hancers of the prior art. 
DISCLOSURE OF THE INVENTION 
It is accordingly one object of the present invention 
to provide a novel penetration enhancer for use in trans 
dermal drug delivery. 
A further object of the present invention is to provide 
as a novel chemical compound, 3-hydroxy-N-methyl 
pyrrolidone having advantageous characteristics as a 
penetration enhancer in transdermal delivery systems. 
A further object of the invention is to provide meth 
ods for preparation of the novel penetration enhancer, 
3-hydroxy-Nmethylpyrrolidone. 
A still further object of the present invention is to 
provide transdermal delivery systems which contain as 
a safe and effective penetration enhancer, 3-hydroxy-N 
methylpyrrolidone. 
Other objects and advantages of the present invention 
will become apparent as the description thereof pro 
ceeds. 
In satisfaction of the foregoing objects and advan 
tages, there is provided by this invention a novel pene 
tration enhancing compound, 3-hydroxy-N-methylpyr 
rolidone. 
There is also provided _by this invention a method for 
preparation of 3-hydroxy-N-methylpyrrolidone which 
comprises conversion of delta-butyrolactone to methyl 
2,4-dibromobutyrate, conversion of the methyl-2,4 
dibromobutyrate to N-methyl-2,4-dibromobutyramide, 
ring closure of the N-methyl-2,4-dibromobutyramide to 
form 3-bromo-N-methyl-2-pyrrolidone, and conversion 
of the 3-bromo-N-methyl-2-pyrrolidone to 3-hydroxy 
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N-methyl-Z-pyrrolidone by reaction with alkali metal 
carbonate. 
The present invention also provides transdermal 
compositions comprising as the penetration enhancer, 
3-hydroxy-N-methyl-Z-pyrrolidone. The present inven 
tion also provides a method for delivery of drugs 
through the human skin which comprises preparation of 
a transdermal drug delivery system containing 3 
hydroxy-N-methylpyrrolidone as a penetration en 
hancer, and applying the transdermal composition to 
the human skin. 
BRIEF DESCRIPTION OF DRAWINGS 
Reference is now made to the accompanying draw 
ings wherein: 
FIG. 1 is a graph showing a comparison of the per 
cent penetration of 131I-labeled Clioquinol when deliv 
ered with 3-hydroxy-N-methylpyrrolidone, N-methyl 
pyrrolidone, and without an enhancer; 
FIG. 2 is a graph showing the percent penetration of 
125I-labelecl Clioquinol using 3-hydroxy-N-methylpyr 
rolidone, N-methylpyrrolidone, and without an en 
hancer; and 
FIG. 3 is an HPLC radiochromatogram of the 5 
chloro-8-hydroxy-7-[l31I]-iodoquinoline, the drug 
chosen to test the penetration enhancing characteristics 
of the compound of the invention. 
BEST MODE FOR CARRYING OUT THE 
INVENTION 
It has been discovered according to this invention 
that 3-hydroxy-N-methylpyrrolidone, also known as 
3-hydroxy-N~methyl-2-pyrrolidone, is an effective pen 
etration enhancer when used in transdermal drug deliv 
ery systems. 3-hydroxy-N-methylpyrrolidone is a novel 
compound prepared according to methods described 
herein. In general, the compound is a white solid having 
a melting point of 7l°-72° C. and is of the following 
structural formula: 
This novel compound is prepared through a series of 
novel chemical steps, preferably using as the basic start 
ing material delta-butyrolactone. In a preferred proce 
dure, delta-butyrolactone is reacted with bromine in the 
presence of a bromide compound such as phosphorus 
tribromide and under an elevated temperature in the 
range of 75°—l25° C. In a preferred procedure, the bro 
mide compound and delta-butyrolactone are mixed 
with agitation and at an elevated temperature, liquid 
bromine is slowly added. The temperature may be con 
trolled in the preferred range by the rate of addition of 
the bromine and by external heating. Preferably the 
amount of bromine added to the butyrolactone is in the 
molecular ratio of about 1:2. Bromine addition is 
stopped when HBr evolution becomes evident, after 
which the reaction mixture is cooled and combined 
with methanol. The resulting solution is then saturated 
with HCl gas, the methanol is removed and methyl-2,4 
dibromobutyrate is removed as a pale yellow liquid. 
In a second step of the reaction, the methyl-2,4 
dibromobutyrate is reacted with methylamine in an 
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aqueous solution at a temperature of below ambient in 
order to form N-methyl-2,4-dibromobutyramide. Then 
butyramide is then recovered and puri?ed to obtain the 
solid intermediate product. 
The N-methyl-2,4-dibromobutyramide is then con 
verted to 3-bromo-N-methyl-Z-pyrrolidone by reaction 
with alkali metal alkoxide to effect ring closure. In this 
reaction, an alcoholic solution of the N-methyl2,4-> 
dibromobutyramide is formed and freshly prepared 
alkali metal alkoxide, preferably sodium ethoxide, is 
added drop-wise to the mixture under an inert atmo 
sphere. After the reaction is complete, the mixture is 
?ltered and the alcohol removed under reduced pres 
sure. This solid intermediate is then purified to provide 
a yellow liquid intermediate product. 
The ‘recovered 3-bromo-N-methyl-Z-pyrrolidone is 
then converted to the 3-hydroxy-N-methyl-2-pyrroli 
done of this invention by reaction with an alkali metal 
or alkaline earth metal carbonate in a substantially stoi 
chiometric reaction and in an aqueous medium, Prefera 
bly the reactant is added to a solution of the 3-bromo-N 
methyl-Z-pyrrolidone under agitation and while heating 
in the range of 75°—l25° C. After the reaction is com 
plete, the 3-hydroxy-N-methylpyrrolidine white solid 
product is recovered and purified. 
The following is a schematic showing this four-step 
reaction. 
l 2 
Br 
(1) En 
(2) CH3OH E 
B 
COgCHj, 
O 
r 
CH3 
3 4 
OH 
l 
CH3 
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As pointed out above, a penetration enhancer is a 
chemical compound which, when included in a trans 
dermal formulation, affects the skin of a human by in 
creasing permeability of the skin to allow more of a 
drug to be absorbed in a shorter period of time. The 
penetration enhancer is normally contained in a formu 
lation, called a transdermal composition, in combination 
with the appropriate drug to be delivered and other 
known components of the formulation. According to 
this invention, it has been discovered that the 3- hy 
droxy-N-methylpyrrolidone provides unexpectedly 
improved effects as a penetration enhancer when incor 
porated into a transdermal formulation. As mentioned 
herein, N-methylpyrrolidone is a known penetration 
5,032,402 
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enhancer. In studies leading to this invention using the 
prior art compound, N-methyl-Z-pyrrolidone, it was 
discovered that a major metabolite of N-methylpyrroli 
done which is excreted in the urine is 3-hydroxy-N 
methy1-2-pyrro1idone. The subsequent synthesis of this 
compound, and closer examination of physical proper 
ties of the compound, led to the present discovery that 
3-hydroxy-N-methylpyrrolidone possesses several ad 
vantages over similar compounds such as N-methylpyr 
rolidone as a penetration enhancer. Thus, 3-hydroxy-N 
methylpyrrolidone provides at least equal and often 
superior enhancement of transdermal absorption while 
exposing the body to a lower metabolic burden. Fur 
ther, 3-hydroxy-N-methy1pyrrolidone is a “softer” 
xenobiotic to the body because no energy will be ex 
pended in metabolic processes after the compound’s 
absorption into the systemic circulation. Also, in view 
of the apparent safety of N-methylpyrrolidone, its 
major metabolite, 3-hydroxy-N-methylpyrrolidone, 
would be expected to have an even lower toxicity. 
The 3-hydroxy-N-methylpyrrolidone of this inven 
tion may be used as the penetration enhancer in any 
transdermal drug delivery system in which it is effec 
tive. It is considered that the 3-hydroxy-N-methylpyr 
r'olidone is compatible with all known drugs which are 
systematically-active and can be delivered in a trans 
dermal system to be absorbed by the body surface. As is 
known, a transdermal delivery system comprises or 
reservoir for the composition to be transferred includ 
ing the drug of choice, the carrier, and the penetration 
enhancer. In general, the reservoir will be contained 
between a backing member and a pressure-sensitive 
adhesive which enables the transdermal device to be 
applied to the skin. Transdermal delivery systems are 
well known in the art and described, for example, in U. 
S. Pat. Nos. 3,598,122, 3,797,494, and 4,230,105. It is 
considered according to the present invention that the 
penetration enhancer of this invention can be used in all 
such systems. 
In practicing this invention one can employ any sys 
temically active drug which will be absorbed by the 
body surface to which the transdermal bandage is ap 
plied, consistent with their known dosages and uses. Of 
course, the amount of drug necessary to obtain the 
desired therapeutic effect will vary depending on the 
particular drug used. Suitable systemic drugs include, 
without limitation, Anti-microbial agents such as peni 
cillin and tetracycline; Sedatives and Hypnotics such as 
pentabarbital sodium and phenobarbital; Psychic Ener 
gizers such as 3-(2-aminopropyl) indole acetate; tran 
quilizers such as reserpine, chloropromazine hydro 
chloride, and thiopropazate hydrochloride; Hormones; 
Antipyretics such as aspirin, salicylamide, and sodium 
salicylate; morphine and other narcotic analgesics; An 
tidiabetics, e.g., insulin; Cardiovascular Agents, e.g., 
nitroglycerin, and cardiac glycosides such as digitoxin, 
Anti-spasmodics such as atropine, and methscololamine 
bromide; Anti-malarials such as the 4-aminoquinolines; 
and Nutritional Agents such as vitamins, essential amino 
acids, and essential fats. 
Further, topically active drugs consistent with their 
known dosages and uses can be administered. Suitable 
drugs include without limitation: Antiperspirants, e.g., 
aluminum chloride; Deodorants, e.g., hexachlorophene, 
Astringents, e.g., tannic acid; Irritants, e.g., methyl 
salicylate, Keratolytics, e.g., benzoic acid; Antifungal 
Agents; Anti-in?ammatory Agents; Anti-neoplastic 
Agents, And Antibacterial Agents. 
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The above and other drugs can be present in the 
reservoir alone or in combination form with pharma 
ceutical carriers. The pharmaceutical carriers accept 
able for the purpose of this invention are the art known 
carriers that do not adversely affect the drug, the host, 
or the material comprising the drug delivery device. 
Suitable pharmaceutical carriers include sterile water; 
saline, dextrose; dextrose in water or saline; condensa 
tion products of castor oil and ethylene oxide combin 
ing about 30 to about 35 moles of ethylene oxide per 
mole of castor oil; liquid glyceryl triester of a lower 
molecular weight fatty acid; lower alkanols; oils such as 
corn oil; peanut oil, sesame oil and the like, with emulsi 
?ers such as mono-or di-glyceride of a fatty acid, or a 
phosphatide, e.g., lecithin, and the like; glycols; polyal 
kylene glycols; aqueous media in the presence of a sus 
pending agent, for example, sodium carboxymethylcel 
lulose; sodium alginate; poly(vinylpyrolidone); and the 
like, alone, or with suitable dispensing agents such as 
lecithin; polyoxyethylene stearate; and the like. The _ 
carrier may also contain adjuvants such as preserving, 
stabilizing, wetting, emulsifying agents and the like 
together with the penetration enhancer of this inven 
tion. 
The following examples are presented to illustrate the 
invention. However, it is not to be considered as limited 
thereto. In the examples and through the speci?cation, 
parts are by weight unless otherwise indicated. 
EXAMPLE 1 . 
Synthesis of 3-hydr0xy-N-methy1-2-Pyrrolidone 
General. Melting points were determined on a Fish 
er-Johns melting point apparatus and are uncorrected. 
H-NMR and C-NMR spectra were obtained using a 
Varian Gemini 200MHz or Varian XL-300 300 MHZ 
spectrometer. Mass spectra were run on a Kratos M550 
TA mass spectrometer with. a KratosDS90 data system. 
Infrared (IR) spectra were recorded on a Perkin-Elmer 
Ratio Recording spectrophotometer. Microanalysis 
were performed by Atlantic Microlab, Inc., Atlanta, 
Ga. ' 
Reactions were routinely followed by thin layer 
chromatography (TLC) using Whatman K6F silica gel 
plates. Spots were visualized by exposure to iodine 
vapor or uv lamp (254 nm). Column chromatography 
was carried out using silica gel (Davidson Chemical, 
Baltimore, Md.). 
Materials. Delta-Butyrolactone (Aldrich, Cat. No. 
B10,360-8, lot 2710BK, 99%), Bromine (J. T. Baker, 
Cat. No. 1-9760, lot 849381), Phosphorous tribromide 
(Aldrich, Cat. No. 25,653-6, lot 1413BM), methanol 
(Fisher, Cat. No. A-412, lot 854027), Methylamine, 40 
wt % solution in water (Aldrich, Cat. No. M2,775-1, lot 
03804CT), absolute ethanol (Midwest Solvents Com 
pany of I11.), potassium carbonate (Aldrich, Cat. No. 
20,961-9, lot O4006BP, 99+%). 
A. Methyl 2,4'dibromobutyrate. Phosphorous tribroi 
mide (2.0 ml, 5.7 gm, 0.021 mole) was added to ‘del 
tabutyrolactone (100.8 gm, 1.17 mole) and the mixture 
was heated to 100° C. while stirring. Bromine (30 m1, 
93.4 grn, 0.59 mole) was slowly added dropwise beneath 
the surface of the liquid. The temperature was con 
trolled at ll0°-ll5° C. by the rate of addition of bro 
mine and an oil bath. Additional PBT} (1.0 ml, 2.85 gm, 
0.011 mole) was added to the reaction vessel and bro 
mine addition was then continued until HBr evolution 
was evident (approx. 25 ml, 80 gm, 0.49 mole). The 
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reaction mixture was stirred and cooled to room tem 
perature and ?nally cooled in an ice bath. The mixture 
was combined with methanol (480 ml) and the resulting 
solution was saturated with HCl gas. The solution was 
allowed to stand overnight at room temperature after 
which the methanol was removed under reduced pres 
sure. The residue was dissolved in ether, washed with 
5% sodium bicarbonate solution, dried over magnesium 
sulfate and ?ltered. The solvent was removed and the 
residue distilled under reduced pressure to yield a clear 
pale yellow liquid, 2 (216.4 gm, 71%); hp. 80°-85° C. @ 
2-3 mm ofHg, IR(neat) 1775, 1735, 1470 and l380—l130 
cm-l; H-NMR (CDC13) 5 2.54 (q, 2H, -CH2-CHBr-), 
3.55 (t, 2H, Br-CH1-CH2-), 3.81 (s, 3H, O-CH3), 4.56 (t, 
1H, -CH2-CHBr-); C-NMR, decoupled (CDC13) 29.60, 
36.69, 43.24, 53.10, 169.77 ppm. Anal. calcd. for 
C5H3O2Br2 (295.934): C, 23.10; H, 3.10. Found: C, 
23.39; H, 3.14%. 
B. N-Methyl-2,4-dibromobutyramide. Methyl 2,4 
dibromobutyrate (50 gm, 0.192 mole) was mixed with 
40 wt % methylamine in aqueous solution (20.0 ml, 7.22 
gm, 0.232 mole) with stirring and cooling in an ice bath. 
The reaction mixture was stirred for 16 hours at 5° C., 
chloroform (100 ml) was then added and the organic 
layer washed with water. The organic extract was dried 
over magnesium sulfate, ?ltered and the solvent re 
moved. The crude product was puri?ed by column 
chromatography (silica gel, gradient elution hexane/ 
chloroform to chloroform/ethylacetate) to yield an 
off-white solid, (25.4 gm, 51.7%): m.p. 42°-47° C. The 
compound was used in the next step without further 
puri?cation. A small portion was further puri?ed for 
elemental analysis; m.p. 48°—49° C. IR(KBr) 3450, 1660, 
1570, 1415, 1240 and 1210 cm-1; H-NMR (CDC13) 
62.48 (m, 1H, -CH2-CHBr-), 2.79(m, 1H, -CH2-CHBy-), 
(d, 3H, -NH2-CH3-), 3.55 (t, 2H, Br-CHZ-Cl-h), 4.54 
(dd, lH,"CHBr-); 6.39 (s, broad, 1H, -NH-CH3), C 
NMR, decoupled (CDC13) 26.83, 30.27, 37.60, 48.26, 
168.65 ppm. Anal. calcd. for C5H9NBr2O (258.949): C, 
23.19; H, 3.50; N, 5.41. Foundrc, 23.53; H, 3.44; N, 
5.29%. 
C. 3-Bromo-N-methyl-2-pyrr0lidone. To a stirred 
solution of N-methyl-2,4-dibromobutyramide (25.9 gm, 
0.1 mole) in 65 ml of dry ethanol, kept under nitrogen, 
was added dropwise an equimolar quantity of freshly 
prepared sodium ethoxide (2.3 gm Na in 50 ml ethanol) 
over 40 minutes. After two hours the mixture was ?l 
tered and the ethanol removed under reduced pressure. 
The residue was dissolved in chloroform and washed 
with water, then washed with saturated aqueous NaCl. 
Removal of the solvent and distillation under reduced 
pressure yielded a yellow liquid, (11.55 gm, 65.2%); b.p. 
90°-94° C. @ 0.1-1 mm. IR(neat) 1700, 1495,1440, 1405 
and 1300 cm-1; H-NMR (CDCl3) 8 2.32 (m, 1H, -CH2 
CHBr-), 2.72 (sextet, 1H, -CH2-CHBr-), 2.90 (s, 3H, 
-N-CH3), 3.32 (m, 1H, N-cH2-CH3-), 3.58 (m, 1H, N 
CH2-CH2-), 4.42 (dd, 1H, -CH2-CHBr-); C-NMR, de 
coupled (CDC13) 33.6, 35.1, 44.2, 47.5, 171.5 ppm. Anal. 
calcd. for C5H3B1'NO (178.03): C, 33.73; H, 4.53; N, 
7.87. Found: C, 33.81; H, 4.52; N, 7.82%. 
D. 3-Hydroxy-N-methyl-2-pyrrolidone -3-Bromo-N 
methyl-Z-pyrrolidone (2.0 gm, 0.011 mole) was dis 
solved in 100 ml of puri?ed water. Potassium carbonate 
(2.33 gm, 0.017 mole) was added while stirring and the 
mixture was heated to l0O°-110° C. After 4 hours, the 
reaction mixture was poured onto ice and neutralized 
with 1% aqueous HCl. Water was removed under re 
duced pressure and the residue extracted with boiling 
8 
95% ethanol. After removal of the solvent, the product 
was puri?ed by column chromatography (silica gel, 
gradient elution using from chloroform to chloroform 
/ethylacetate/methanol) to yield a white solid, (0.754 
gm, 58.5%); m.p. 71°—72° C. IR(nujol) 3120(broad), 
' 1670, 1400, 1305,‘ 1270 and 1170 cm31 1; H-NMR 
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(CDCl3) 8 1.98 (m, 1H, -CH2-CHOH-), 2.41 (m, 1H, 
-CH2-CHOH-), 2.84 (s, 3H, ~N-CH3), 3.30 (m, 2H, 
-CH2-N-), 4.30 (triplet of doublets, 1H, -CH-OH), 5.18 
(d, 1H, -CH-OH), C-NMR, decoupled (CDC13) 27.38, 
-CH2-CHOH-), 29.74 (-N-CH3), 45.74 (-CH2-N-), 69.41 
(-CH-OH-), 175.53 -CHOH-CO-N-) ppm. Partially de 
coupled and Z-dimensional HETCOR spectra support 
the assignments as given. Anal. calcd. for C5H9NO2 
(115.129): C, 52.16; H, 7.88; N, 12.17%. Ms(70eV) - 
Extract molecular ion M+ calculated for 115.06332, 
Found: 115.0634. Fragmentation pattern: 86 (M-29); 54 
(M-58); 42 (M-73). 
EXAMPLE 2 
Radioiodination of 5-chloro-8-hydroxy-iodoquinoline. 
This example prepares the radioiodinated control, 
5-chloro-8-hydroxy-iodoquinoline to be used in tests 
described hereinafter to determine the effect of penetra 
tion of the 3-hydroxy-N-methylpyrrolidone of this in 
vention. 
Materials. Sodium Iodide-125 (New England Nuclear 
NEZ 033, radiochemical and radionuclidic purity 
99%), Sodium iodide-131 (New England Nuclear NEZ ; 
035H, radiochemical and radionuclidic purity 99%), 
5-chloro-8-hydroxy quinoline hydrochloride (Aldrich, 
lot 3128LJ Cat No. 25,044-9), 5-chloro-8-hydroxy 
7iodoquinoline (Aldrich, lot 0513KL Cat. No. 
22,406-5), Iodobeads (Pierce Chemical Company No. 
28666). 
Synthesis of 5-chloro-8-hydroxy-7[l25I]-lodoquino 
line. An aqueous solution (0.1N NaOH) containing ap 
proximately one mCi of Nal25I was diluted to 0.5 ml 
with methanol. Three iodobeads were added and the 
solution was left to stand for 5 minutes at room tempera 
ture. 5-Chloro-8-hydroxyquinoline (0.5 ml of a stock 
solution containing 200 ug/ml in methanol) was added 
and the reaction vessel was shaken occasionally for 30 
minutes. The iodobeads were then removed, 5-chloro-8 
hydroxy-7-iodoquinoline (5.0 ml of a stock solution 
containing 1 mg/ml in methanol) was added followed 
by 20.0 ml of puri?ed water. The resulting white precip 
itate was ?ltered and washed with water until the ?l 
trate activity was at background levels. The product 
was then dissolved in CHZCLZ (10 ml), transferred to a 
25 ml pearshaped ?ask and the solvent removed under ‘ 
reduced pressure. Assay by uv spectroscopy at 256 nm 
showed that 4.84 mg of 5-chloro-8-hydroxy-7 
iodoquinoline were recovered. Speci?c activity approx 
imately lZOuCi/mg. 
Synthesis of 5-chloro-8-hydroxy-7-[13lIl-lodoquino 
line. This compound was prepared by the same proce 
dure described above using Naml. 
Assessment of Radiochemical .Purity; Analysis and 
identi?cation of radiolabeled 5-chloro-8-hydroxy-7 
iodoquinoline and determination of radiochemical pu 
rity was performed by HPLC. The HPLC system used 
consisted of the following components: isocratic pump 
(Altex model 110A, Berkley, Calif), ?xed volume injec 
tor (Rheodyne model 7125, Cotari, Calif), Waters u 
Bondapak TM 018 reverse phase column (Waters Ass., 
Milford, Mass.),_uv detector (Waters model 440, Mil 
9 
ford, Mass), Radiomatic Model ES stream splitter 
(Radiomatic Instruments and Chemicals, Tampa, Fla.), 
Radiomatic Model HP ?ow-through radioactivity de 
tector (Radiomatic Instruments and Chemicals, Tampa, 
Fla.), dual channel strip chart recorder (Linear Instru 
ments Inc., model 858, Irvine, Calif). _ 
Samples were introduced using a 50ul ?xed volume 
injection loop. A mobile phase containing 70% metha 
nol (Fisher HPLC grade, lot 874675) and 30% 0.05M 
phosphoric acid (Eastman, lot 620) was ?ltered using a 
0.22u ?lter, degassed under vacuum and delivered at a 
flow rate of 1.0 ml/min. After passing through the col 
umn, the mobile phase effluent passed through the uv 
detector set at 254 nm and was split by the stream split- ' 
ter. A percentage of the effluent was sent to the flow 
through radioactivity detector and the remainder di 
verted to waste. This detector mixed scintillation coc 
tail (Scintiverse LC, Fisher) with the effluent in a ratio 
of 4:1 (v/v). The uv output was recorded on one chan 
nel of the strip chart recorder and the radioactivity _ 
output was recorded simultaneously on the second 
channel. 
Standards were prepared by dissolving 5.0 mg of 
unlabeled 5—chloro-8-hydroxy-7-iodoquinoline or 5.0 
mg of S-chloro-8-hydroxyquinoline in 100 ml of mobile 
phase to make a ?nal concentration of 50 ug/ml. Radio 
active samples were prepared by dissolving the reaction 
product (4.84 mg) in methanol, taking a small aliquot 
(100 ul), evaporating and reconstituting in mobile phase. 
The retention time for 5-chloro-8-hydroxy-7 
iodoquinoline was 10.5 minutes. 5-chloro-8-hydrox 
yquinoline eluted with the solvent front at 3 minutes. 
An HPLC chromatogram for 5-chloro-8-hydroxy-7 
[131I]-i0doquinoline is shown in FIG. 3. In FIG. 3, the 
upper tracing represents UV detection of radioiodina 
tion product at 254 nm; A: solvent front/ 5-chloro-8 
hydroxyquinoline, B: 5-chloro-8-hydroxy-7-iodoquino 
line. Lower tracing represents radioactivity detection 
which was monitored continuously using a flow 
through liquid scintillation counter. Only one radioac 
tive peak (lower tracing) was detected that corresponds 
to the uv peak of 5-chloro-8-hydroxy-7-iodoquinoline. 
EXAMPLE‘ 3 
In vitro penetration of radioiodinated 
S-chloro-8-hydroxy-7-iodoquinoline. 
General. Standard Franz diffusion cells (15 mm id, 
O-ring design) were manufactured by Crown Glass 
Inc., Somerville, N. J. The cell caps were modi?ed with 
ground glass joints to ?t 14/20 ground glass stoppers. A 
Franz diffusion cell drive consol F-DCD-9 was also 
manufactured by Crown Glass. A Vandercamp 2500 
recirculating water bath was used to maintain the cells 
at 37° C. Split thickness human allograph tissues (0.015 
in. thickness), thigh back area, was ‘obtained from the 
Tissue Transplant Bank, St. Agnes Medical Center, 
Philadelphia, Pa. Samples were counted in a Packard 
Auto-Gamma Scintillation Spectrometerv 
Materials. Sterile Saline (0.9% Sodium Chloride 
USP, Travenol, NDC 0338-0049-04 lot 0056747), Albu 
min (Bovine, fraction v, Sigma A-4503 lot l27F-0877), 
N-Methyl-Z-pyrrolidone (Aldrich 99+% Cat No. 
24,279-9 lot 04402TP), Neomycin Sulfate (Sigma N 
1876 lot 66F-0l51), absolute ethanol (Midwest Solvents 
Company of 111.). 
Procedure. Human allograph tissue, which had been 
stored at —-70° C., was thawed and immediately 
mounted in a Franz type diffusion cell. The receptor 
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chamber was ?lled with normal saline containing 2% 
albumin and 0.05% neomycin sulfate. Each cell was 
maintained at 37° C. and stirred at 600 rpm. After the 
cells had been allowed to equilibrate for 4 to 6 hours, 
200 ul of a saturated ethanolic solution of 5-chloro-8 
hydroxy-7-[l25I]-iodoquinoline (approx. 470 uCi, 0.44 
mg) was applied to the donor side of each cell. This was 
immediately followed by either 200 pl of absolute etha 
nol for the control cells, 200 pl of 50% (w/v 3-hydroxy 
N-methylpyrrolidone in ethanol or an equimolar etha 
nolic solution of N-methylpyrrolidone (43.1% w/v). 
The cells were then capped with ground glass stoppers. 
At various time intervals, over an 80—100 hour period, 
the entire contents of the receptor chamber was re 
moved with a 10cc syringe and placed into a vial. The 
receptor chamber was then re?lled with fresh solution. 
After the last collection these vials were placed in a 
well-type gamma counter and counted for I-l25 activ 
ity. 
At the time of dosing 200 pl of the saturated 5-chloro 
8-hydroxy-7-[l25I]-iodoquinoline solution was placed 
into separate vials to calculate the amount of activity 
(dose) applied to the skin. 
EXAMPLE 4 
In this example, 3-hydroxy-N-methyl pyrrolidone 
was tested for its use as a percutaneous penetration 
enhancer. In vitro studies were carried out using Franz 
type diffusion cells. The penetration enhancing proper 
ties of 3-hydroxy-N-methylpyrrolidone was compared 
to N-methyl pyrrolidone, a compound known to en 
hance the penetration of drugs through the skin. 
For these in vitro studies radioiodinated 5-chloro-8 
hydroxy-7-iodoquinoline was chosen as a model drug. 
This drug, known as Clioquinol USP, is currently mar 
keted by Ciba (Ciba Pharmaceutical Company, 556 
Morris Avenue, Summit, N. J. 07901), as a topical an 
tibacterial/antifungal agent tradenamed Vioform TM . It 
was chosen because 1) it is a drug that is absorbed very 
slowly through the skin and 2) Clioquinol inherently 
has iodine in its structure, allowing easy preparation of 
a radiolabeled analogue. This radiolabeled marker is 
conveniently used to follow the penetration of the drug 
through the skin. 
Franz diffusion cells are designed to mimic in vivo 
conditions. A ?nite dose of drug is applied to the stra 
' tum corneum side of the skin and penetration is fol 
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lowed by analyzing for the drug in the receptor phase 
underneath. In these studies the amount of drug cross 
ing the skin barrier is estimated by counting total radio 
activity in the receptor phase. While no excised tissue 
has been found to duplicate in vivo absorption in hu 
mans, excised human skin is generally regarded as the 
best substitute and was therefore used in these studies. 
In a preliminary study, the transdermal absorption of 
Clioquinol was evaluated in the presence of 3-hydroxy 
N-methylpyrrolidone, N-methylpyrrolidone, and in the 
absence of enhancer. An ethanolic solution of [I-l3l] 
Clioquinol was applied to 3 cells followed by either 
ethanol (control), 50% 3-hydroxy-N~methyl-pyrroli 
done in ethanol or an equimolar solution of N-methyl 
pyrrolidone. In FIG. 1, the percent penetration of 5 
chloro-8-hydroxy-7-[131I]-iodoquinoline through 
human skin is illustrated. The amount of 5-chloro-8 
hydroxy-7-[l3lI]-iodoquinoline activity applied is equal 
to 100%. As shown in FIG. 1, the extent of enhance 
ment by 3-hydroxy-N-methyl-pyrrolidone is clearly 
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evident. At 48.5 hours the amount of I-l31 Clioquinol 
that had penetrated through the skin in the presence of 
3-hydroxy-N-methyl-pyrrolidone (10.2% absorbed) 
was 3.9 times greater than the control (2.6% absorbed) 
and 1.5 times more than with N-methylpyrrolidone 
(6.5% absorbed). 
The study was repeated using I-l25 labeled Cli 
oquinol. Iodine-125 was used because the longer half 
life (ti =60d) and lower energy gamma ray (0.035 Mev) 
were better suited to our experimental design. The re 
. sults are shown in FIG. 2. In FIG. 2, the percent pene 
‘tration of 5-chloro-8-hydroxy-7-[125I]-iodoquinoline 
through the human skin is illustrated. The amount of 
5-chloro-8-hydroxy-7P25I]-iodoquinoline applied is 
equal to 100%. The relative order of enhancement was 
found to be the same with 3-hydroxy~N-methylpyr 
rolone>N-methylpyrrolone>control. The amount of 
Clioquinol penetrating the skin in the presence of 3 
hydroxy-N-methylpyrrolidone (40.0% absorbed) was 
1.8 times higher than the control (19.5% absorbed) and 
1.3 times greater than with N-methyl-pyrrolidone 
(27.8% absorbed ) at 85.5 hours. Alternatively, the same 
amount of Clioquinol was absorbed in approximately 32 
hours in the presence of 3-hydroxy-N-methylpyrroli 
done (19% absorbed) as was absorbed in 85 hours in the 
absence of 3-hydroxy-N-methylpyrrolidone. 
The results of these experiments indicate that 3 
hydroxy-N-methylpyrrolidone shows great potential 
for use as a percutaneous penetration enhancer. The 
absorption of Clioquinol was clearly increased in the 
presence of 3-hydroxy-N-methylpyrrolidone as com 
pared to its absorption in the presence of ethanol and 
N-methylpyrrolidone. In addition, since 3-hydroxy-N 
methylpyrrolidone is a major metabolite of N-methyl 
pyrrolidone, it should offer the advantage of being a 
lower toxicological burden to the body. 
The mechanism by which penetration enhancers 
exert their effects has not been clearly established. Pos 
sible modes of action that have been suggested include 
altering membrane fluidity in the stratum corneum, 
altering the partitioning behavior of the drug between 
the stratum corneum and the underlying dermal tissues 
and solubilizing the lipid components of the stratum 
corneum. Most likely penetration enhancers work by a 
combination of these and other mechanisms with one 
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mechanism being more dominant than others for a par 
ticular type of enhancer. Although the mechanism is 
not known, since 3-hydroxy-N-methylpyrrolidone ef 
fectively enhances the absorption of a poorly absorbed 
compound like Clioquinol, this suggests that 3-hydroxy 
N-methylpyrrolidone will be effective for enhancing 
the percutaneous absorption of many other poorly ab 
sorbed compounds. 
In conclusion, a novel compound, 3-hydroxy-N 
methylpyrrolidone, was synthesized and was shown to 
effectively enhance the in-vitro absorption of a model 
drug. Further, 3-hydroxy-N-methylpyrrolidone is 
shown to be more effective than N-methylpyrrolidone 
in enhancing the absorption of drugs. Because it is a 
metabolite, 3-hydroxy-N-methylpyrrolidone should be 
metabolically softer to the body and less irritating than 
other compounds such as N-methylpyrrolidone. The 
introduction of a potent, non-toxic and non-irritating 
compound that can effectively enhance the penetration 
of poorly absorbed drugs would open the way for the 
clinical use of transdermal therapeutic systems contain 
ing drugs that otherwise could not be administered by 
this route. 
The invention has been described herein with refer 
ence to certain preferred embodiments. However, as 
obvious variations thereon will become apparent to 
those skilled in the art, the invention is not to be consid 
ered as limited thereto. 
We claim: I 
1. An article of manufacture for the continuous ad 
ministration of drugs by absorption through the skin 
which comprises as a penetration enhancer for the drug, 
3-hydroxy-N-methylpyrrolidone. 
2. An article of manufacture according to claim 1 
wherein the article of manufacture comprises a reser 
voir for the drug and the penetration enhancer, a back 
ing member, and a pressure-sensitive adhesive for appli 
cation of the article to the skin. 
3. A method for the administration of drugs through 
the human skin which comprises preparation of a drug 
delivery system which contains the drug and as a pene 
tration enhancer, 3-hydroxy-N-rnethylpyrrolidone, and 
applying the composition to the human skin. 
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